Navigation Links
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster
Date:7/20/2009

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development.

The collaboration will begin with a selection of ten small molecule candidates, discovered by LLS grant-funded academic researchers, deemed to have the most promise of advancing into clinical trials in the shortest period of time. FORMA will use its proprietary Computational Solvent (CS) Mapping technology to aid in structure based drug design with expert computer modeling, screening and medicinal chemistry competence to optimize and prioritize molecules that LLS and its partners may take to the clinic.

The partnership between LLS and FORMA is the latest in LLS's Therapy Acceleration Program (TAP), a bold initiative intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. Through TAP, LLS is taking a results-oriented approach, partnering directly with biotechnology companies to move promising therapies more quickly along the FDA drug approval critical path.

"With its sophisticated technology suite and internal expertise to expeditiously progress the development of novel therapies, FORMA is an ideal partner to help LLS identify and optimize the most promising drug candidates and to achieve our mission of advancing life-saving blood cancer therapeutics," said John Walter LLS's chief executive officer.

"LLS has assembled a promising portfolio of innovative programs to combat a wide range of hematological cancers," says FORMA CEO Steve Tregay, Ph.D. "The team at FORMA is excited to be working with LLS on this bold initiative by providing our unique suite of drug discovery technologies to quickly translate science from the laboratory to patients in clinical trials."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About FORMA Therapeutics

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. Capitalizing on the targets and pathways validated by the Cancer Genome Atlas Project and other related efforts, FORMA is developing a new generation of cancer therapies aimed at previously elusive drug targets. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing. www.formatherapeutics.com.

    Contact: LLS: Andrea Greif
            (914) 821-8958  andrea.greif@lls.org

    FORMA:   Steven Tregay, CEO
             (617) 679-1970

    FORMA Media Contact:
    MacDougall Biomedical Communications
    Douglas MacDougall or Jennifer Conrad
    (781) 235-3060


'/>"/>
SOURCE The Leukemia & Lymphoma Society (LLS)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leukemia/Lymphoma Society Pleased to Announce Partnership in Southern Ohio with Eisen Marketing Group
2. 2009 recipient of minority scholar award begins clinical research on leukemia
3. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
4. New Drug Could Work Against Leukemia
5. Leukemia & Lymphoma Society Recognizes Aurora Physician as Man of the Year
6. For Kids With Leukemia, Radiation May Be Safe to Skip
7. The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense
8. Taking Aim at Relapse of Leukemia in Kids
9. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
10. Study IDs benefit of donor SCT for adults with acute myeloid leukemia
11. Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced ... chair for Orange County health care system CalOptima Friday. CalOptima announced its election ... Mark Refowitz’s term, which runs through June 30 of this year, until another ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, the ... 34 percent to $6.7 billion and can be expected to grow at ... five years, from $6.7 billion in 2016, to $22.6 billion in 2021. ... to purchase cannabis without a doctor,s recommendation. Voters in California ...
(Date:3/27/2017)... 2017 The staggering cost of cancer treatment ... access to the latest treatment options against cancer. Even ... patients have inadequate or no health insurance and are ... Access to modern cancer treatment is almost non-existent for ... The mission statements of pharmaceutical and biotech companies ...
Breaking Medicine Technology: